ALTH Allos Therapeutics, Inc.

[greencat]

ALTH broke out of a rugged consolidation pattern but still had higher lows.. It should tap $9.00 with no problem.

ALTH Chart


Allos Therapeutics, Inc.
11080 Circlepoint Road
Suite 200
Westminster, CO 80020
United States - Map
Phone: 303-426-6262
Fax: 303-412-9160
Web Site: Allos Therapeutics - Home

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 170


BUSINESS SUMMARY
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics. It is developing FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The company is also developing FOLOTYN as a single agent and in combination therapy regimens in various hematologic malignancies and solid tumor indications, including stage IV breast cancer and recurrent/metastatic head and neck cancer. It sells FOLOTYN to pharmaceutical wholesale distributors who then resell it to patients’ respective health care providers. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.

[greencat]

AALTH made a higher low. Expect it to break over old highs.

ALTH Chart


Allos Therapeutics, Inc.
11080 Circlepoint Road
Suite 200
Westminster, CO 80020
United States - Map
Phone: 303-426-6262
Fax: 303-412-9160
Web Site: Allos Therapeutics - Home

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 170


BUSINESS SUMMARY
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics. It is developing FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The company is also developing FOLOTYN as a single agent and in combination therapy regimens in various hematologic malignancies and solid tumor indications, including stage IV breast cancer and recurrent/metastatic head and neck cancer. It sells FOLOTYN to pharmaceutical wholesale distributors who then resell it to patients’ respective health care providers. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.[/QUOTE]